16 / 17
Page 64
conferenceseries
.com
Volume 7, Issue 4(Suppl)
J Gastrointest Dig Syst, an open access journal
ISSN: 2161-069X
Gastro Congress 2017
September 11-12, 2017
September 11-12, 2017 | Paris, France
12
th
Euro-Global Gastroenterology Conference
Study of the role of Terlipressin in the treatment of Hepatorenal syndrome
Ibrahim Marwa
Alexandria University, Egypt
Background:
Hepatorenal syndrome (HRS) is the development of progressive renal failure in patients with advanced chronic liver
disease, occasionally fulminant hepatitis, who havemarked circulatory dysfunction, the definitive treatment forHepatorenal syndrome
is Liver transplantation, and all other therapies can best be described as bridges to transplantation. Systemic vasoconstrictors are the
most promising pharmacologic agents in the management of HRS.
Objectives:
The aim of the work was to evaluate the precipitative factors in cirrhotic patients who developed Hepatorenal syndrome
and to evaluate the role of Terlipressin in the treatment of Hepatorenal syndrome (type 2)
Patients and Methods:
the study was conducted on 40 cirrhotic patients with Hepatorenal syndrome (type II), randomized into two
groups: Group I consisted of 20 patients who were given Terlipressin, 1mg/8h, intravenous infusion (3mg/day) for 7days, in additional
to conventional treatment of Hepatorenal syndrome (intra venous albumin 1g/kg/day up to 100gm/day).Group II consisted of 20
patients who were given only conventional treatment of Hepatorenal syndrome (intra venous albumin) and was considered as a
control group. All patients were subjected to the following: Detailed history taking and proper clinical examination.
• Arterial blood pressure and urine output
• Laboratory investigations (complete urine analysis, complete blood count, liver function tests (ALT, AST, serum albumin,
prothrombin time and activity, serum bilirubin (total and direct), renal function tests (blood urea and serum creatinine),
serum Na, K, Urinary Na and ascitic fluid analysis
• Ultrasound examination of abdomen
Blood urea and serum creatinine, serum Na, K, Urinary Na were re-evaluated after 7 days of treatment.
Results:
The result of the present study showed that few patients had evident precipitating factors for HRS including hematemesis in
three patients and spontaneous bacterial peritonitis in one patient. After follow up for 7days renal function improved in patients with
Terlipressin treatment (fall in serum creatinine below 1,5 mg\dl), there was no change in renal functions in control group. There were
no ischemic side effects in patients with Terlipressin treatment.
Conclusions:
Terlipressin improves renal functions in patients with Hepatorenal syndrome (type 2).The use of Terlipressin as a
therapeutic option in patients with Hepatorenal syndrome was not associated with significant short term adverse effects. Most of
patients with type 2 Hepatorenal syndrome have no identifiable precipitative factors.
marwaibrahim90@yahoo.comJ Gastrointest Dig Syst 2017, 7:4(Suppl)
DOI: 10.4172/2161-069X-C1-053